Abstract
A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound.
Claims
-
A method for treating acne in a human in need thereof, the method comprising
administering orally to said human doxycycline, or a pharmaceutically acceptable salt thereof,
in an amount that
(i) is effective to treat acne;
(ii) is 10-80% of a 50 mg dose of doxycycline; and
(iii) results in no reduction of skin microflora during a six-month treatment, without administering a bisphosphonate compound.
- The method according to claim 1, wherein said doxycycline is doxycycline monohydrate.
- The method according to claim 2, wherein said doxycycline monohydrate is administered in an amount of 40 milligrams.
- The method according to claim 3, wherein said doxycycline monohydrate is administered by sustained release.
- A method according to claim 4, wherein said doxycycline monohydrate is administered once a day.
- The method according to claim 2, wherein said doxycycline monohydrate is administered in a dose of 20 mg twice a day.
- The method according to claim 1, wherein said doxycycline, or a pharmaceutically acceptable salt thereof, is administered in an amount which provides a serum concentration in the range of about 0.1 to about 0.8 μg/ml.
-
A method for treating acne in a human in need thereof, the method comprising
administering orally to said human doxycycline, or a pharmaceutically acceptable salt thereof,
in an amount that
(i) is effective to treat acne;
(ii) is 40-80% of a 50 mg dose of doxycycline; and
(iii) results in no reduction of skin microflora during a six-month treatment, without administering a bisphosphonate compound.
- The method according to claim 8, wherein said doxycycline is doxycycline monohydrate.
- The method according to claim 9, wherein said doxycycline monohydrate is administered in an amount of 40 milligrams.
- The method according to claim 10, wherein said doxycycline monohydrate is administered by sustained release.
- A method according to claim 11, wherein said doxycycline monohydrate is administered once a day.
- The method according to claim 9, wherein said doxycycline monohydrate is administered in a dose of 20 mg twice a day.
- The method according to claim 8, wherein said doxycycline, or a pharmaceutically acceptable salt thereof, is administered in an amount which provides a serum concentration in the range of about 0.1 to about 0.8 μg/ml.
-
A method for treating acne in a human in need thereof, the method comprising
administering orally to said human doxycycline, or a pharmaceutically acceptable salt thereof, in an amount of 40 mg per day, wherein the amount results in no reduction of skin microflora during a six-month treatment, without administering a bisphosphonate compound.
- The method according to claim 15, wherein said doxycycline is doxycycline monohydrate.
- The method according to claim 16, wherein said doxycycline monohydrate is administered by sustained release.
- A method according to claim 17, wherein said doxycycline monohydrate is administered once a day.
- The method according to claim 16, wherein said doxycycline monohydrate is administered in a dose of 20 mg twice a day.
- The method according to claim 15, wherein said doxycycline, or a pharmaceutically acceptable salt thereof, is administered in an amount which provides a serum concentration in the range of about 0.1 to about 0.8 μg/ml.
Owners (US)
-
Galderma Labortories Inc
(Jul 29 2008)
Explore more patents:
-
Collagenex Pharmaceuticals Inc
(Jul 20 2002)
Explore more patents:
Applicants
-
Galderma Lab Inc
Explore more patents:
Inventors
CPC Classifications
-
A61K31/135
Explore more patents:
-
A61K31/65
Explore more patents:
-
A61K9/0053
Explore more patents:
-
D06M16/00
Explore more patents:
IPC Classifications
-
A61K31/65
Explore more patents:
Download PDF
Document Preview
Document History
- Publication: Oct 22, 2015
-
Application:
Jun 29, 2015
US 201514753544 A
-
Priority:
Jun 29, 2015
US 201514753544 A
-
Priority:
Dec 9, 2013
US 201314101030 A
-
Priority:
Mar 15, 2013
US 201313838559 A
-
Priority:
Oct 20, 2011
US 201113277789 A
-
Priority:
Oct 22, 2007
US 87647807 A
-
Priority:
Jan 14, 2004
US 75765604 A
-
Priority:
Apr 5, 2002
US 11770902 A
-
Priority:
Sep 26, 2001
US 32548901 P
-
Priority:
Apr 5, 2001
US 28191601 P